文献速递慢阻肺

口服硝酸盐补充增强慢阻肺肺康复:ON-EPIC多中心双盲安慰剂对照随机平行组研究

Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study.
PubMed 文献 · Thorax · 2020-05-06

该多中心双盲安慰剂对照随机平行组研究纳入165例GOLD II-IV级慢阻肺患者,随机分配至富含硝酸盐甜菜根汁组或安慰剂组,在8周肺康复训练前3小时饮用。结果显示活性组增量穿梭步行试验距离改善更显著,中位变化+60米 vs +30米,估计治疗效应30米(95%CI 10至40),且收缩压下降更明显,治疗效应-7 mmHg(95%CI 7至-20),无显著严重不良事件。

要点

  • 硝酸盐补充组ISWT距离中位改善+60米,优于安慰剂组+30米,估计治疗效应30米(95%CI 10至40)
  • 活性组收缩压变化-5.0 mmHg,对照组+6.0 mmHg,估计治疗效应-7 mmHg(95%CI 7至-20)
  • 未报告显著严重不良事件或副作用,耐受性良好

核心结论

  • 膳食硝酸盐补充似乎是增强慢阻肺患者肺康复获益的良好耐受且有效的策略。

研究设计与样本

  • 多中心、双盲、安慰剂对照、随机平行组研究,在英国四个中心进行。
  • 纳入GOLD II-IV级慢阻肺且MRC呼吸困难评分3-5分或存在功能受限的成人,随机1:1分配至富含硝酸盐甜菜根汁(140 mL,含12.9 mmol硝酸盐)或硝酸盐去除安慰剂,每次肺康复前3小时饮用。
  • 共招募165例参与者,78例随机至活性组,87例随机至安慰剂组;主要结局为增量穿梭步行试验距离变化。

主要发现

  • 活性组(n=57)ISWT距离中位变化+60米(IQR 10, 85),安慰剂组(n=65)+30米(IQR 0, 70),估计治疗效应30米(95%CI 10至40),p=0.027。
  • 活性组收缩压变化-5.0 mmHg(-5.0, -3.0),对照组+6.0 mmHg(-1.0, 15.5),估计治疗效应-7 mmHg(95%CI 7至-20),p<0.0005。
  • 未报告显著严重不良事件或副作用。

临床怎么用

  • 对于参加肺康复的GOLD II-IV级慢阻肺患者,可考虑在每次康复训练前3小时补充富含硝酸盐的甜菜根汁以增强运动能力获益。
  • 该干预可能同时有助于降低收缩压,但需结合患者个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Dietary nitrate supplementation has been proposed as a strategy to improve exercise performance, both in healthy individuals and in people with COPD. We aimed to assess whether it could enhance the effect of pulmonary rehabilitation (PR) in COPD. METHODS: This double-blind, placebo-controlled, parallel group, randomised controlled study performed at four UK centres, enrolled adults with Global Initiative for Chronic Obstructive Lung Disease grade II-IV COPD and Medical Research Council dyspnoea score 3-5 or functional limitation to undertake a twice weekly 8-week PR programme. They were randomly assigned (1:1) to either 140 mL of nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate), or placebo nitrate-deplete BRJ, consumed 3 hours prior to undertaking each PR session. Allocation used computer-generated block randomisation. MEASUREMENTS: The primary outcome was change in incremental shuttle walk test (ISWT) distance. Secondary outcomes included quality of life, physical activity level, endothelial function via flow-mediated dilatation, fat-free mass index and blood pressure parameters. RESULTS: 165 participants were recruited, 78 randomised to nitrate-rich BRJ and 87 randomised to placebo. Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027. Active treatment also impacted on systolic blood pressure: treatment group -5.0 mm Hg (-5.0, -3.0) versus control +6.0 mm Hg (-1.0, 15.5), estimated treatment effect -7 mm Hg (95% CI 7 to -20) (p<0.0005). No significant serious adverse events or side effects were reported. CONCLUSIONS: Dietary nitrate supplementation appears to be a well-tolerated and effective strategy to augment the benefits of PR in COPD. TRIAL REGISTRATION NUMBER: ISRCTN27860457.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Pavitt MJ, Tanner RJ, Lewis A, et al. Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study. Thorax. 2020. PMID: 32376732. doi:10.1136/thoraxjnl-2019-214278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。